Does Linagliptin And Metformin Hydrochloride Interact with Acetazolamide?
CDI records a major classification for Linagliptin And Metformin Hydrochloride and Acetazolamide. The stored summary is: Carbonic anhydrase inhibitor that decreases serum bicarbonate and induces metabolic acidosis, increasing risk of lactic acidosis with linagliptin and metformin. The mechanism involves decreases serum bicarbonate and induces non-anion gap, hyperchloremic metabolic acidosis. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Linagliptin And Metformin Hydrochloride Class
- Dipeptidyl Peptidase 4 Inhibitor
- Acetazolamide Class
- Carbonic Anhydrase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Decreases serum bicarbonate and induces non-anion gap, hyperchloremic metabolic acidosis
What To Tell Your Doctor or Pharmacist
If you are taking Linagliptin And Metformin Hydrochloride and your doctor is considering prescribing Acetazolamide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider